1. Home
  2. ASAN vs ZYME Comparison

ASAN vs ZYME Comparison

Compare ASAN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asana Inc.

ASAN

Asana Inc.

HOLD

Current Price

$8.90

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$25.27

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASAN
ZYME
Founded
2008
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
ASAN
ZYME
Price
$8.90
$25.27
Analyst Decision
Hold
Strong Buy
Analyst Count
14
11
Target Price
$12.46
$38.90
AVG Volume (30 Days)
5.2M
408.6K
Earning Date
06-02-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
27.93
33.33
EPS
N/A
N/A
Revenue
$790,806,000.00
$105,965,000.00
Revenue This Year
$10.19
$183.10
Revenue Next Year
$7.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.25
38.87
52 Week Low
$5.38
$13.48
52 Week High
$15.71
$29.75

Technical Indicators

Market Signals
Indicator
ASAN
ZYME
Relative Strength Index (RSI) 60.86 61.35
Support Level $5.77 $22.10
Resistance Level $9.34 $26.92
Average True Range (ATR) 0.52 0.97
MACD 0.07 0.33
Stochastic Oscillator 73.77 94.47

Price Performance

Historical Comparison
ASAN
ZYME

About ASAN Asana Inc.

Asana Inc is the system of action for work, built for the Agentic Enterprise. It provides a comprehensive solution where humans and AI agents can collaborate effectively so that individuals work smarter, teams move faster, and organizations deliver results. Companies use Asana to connect their work to company goals and orchestrate mission-critical workflows like product launches, employee onboarding, resource planning, tracking company-wide strategic initiatives and more. It manages its operations and allocates resources as a single operating and reportable segment. The company generates revenues from subscriptions from paying customers accessing its cloud-based platform.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: